The Brazilian health regulatory agency, Anvisa, has revealed that there are now 65 suspected deaths linked to the use of weight loss pens, specifically those containing the active ingredients semaglutide, liraglutide, and tirzepatide. This alarming figure comes after an update from Anvisa, indicating a steep rise in both fatalities and adverse events associated with these medications. Previously, only six deaths were being investigated, highlighting a significant escalation in the concern over these products.

The suspected deaths occurred between December 2018 and December 2025, a timeline that suggests ongoing issues with the safety of these drugs. Anvisa stated that the number of reported adverse events has surged from 225 to 2,436, underscoring the need for rigorous monitoring and regulation of pharmaceuticals, especially those marketed for weight loss. This matter not only raises questions about the efficacy of these treatments but also about the potential risks they pose to consumers.

The investigation into these deaths reflects Anvisa's commitment to pharmacovigilance, although it emphasizes that they analyze not individual cases but rather the overall data from notifications received. The increasing notifications serve as crucial evidence in understanding the broader impact of these medications on public health. As the agency continues to investigate, there will be heightened scrutiny on the manufacturers and the distribution of these weight loss pens, aiming to ensure safety and accountability in the pharmaceutical industry.